Executive Team

Executive Team

As President and CEO of Waters Corporation, Dr. Udit Batra brings more than two decades of leadership and operational expertise in healthcare and life sciences. He has a proven track record of leading multi-billion-dollar global organizations and driving results at the top of the industry.

Before joining Waters in September 2020, Udit served as CEO of MilliporeSigma, a global business with $8 Billion in sales and over 22,000 employees. In 2015, Udit led the formation of MilliporeSigma, the largest merger in the life science tools industry at the time and built it into one of the top performers in the industry with record sales growth and margin development. From 2011-2013, as CEO of Merck KGaA’s consumer health business, Udit led a period that doubled the business’s profitability and achieved organic growth in the top tier of the industry.

Earlier in his career, Udit served in a range of leadership positions at Novartis. In addition to leading Corporate Strategy and Global Public Health and Market Access for Vaccines and Diagnostics, he also served as president of the Australia Pharma business. During his tenure, this subsidiary became the fastest-growing business amongst competitors in Australia and in Novartis. Throughout his career, Udit has championed science education, especially for low-income students, developed and promoted women’s leadership, and has been a strong advocate for increasing diversity across the organizations he has led.

Udit has received numerous leadership accolades and recognition, including 2023 University of Delaware Alumni Wall of Fame, 2022 PharmaVOICE Hall of Fame, 2021 Mass Technology Leadership Council’s Tech Top 50, 2020 New Englander of the Year by the New England Council, 2019 New England Choice Awards Business Person of the Year, PharmaVOICE Top 100 Most Inspirational People (2017 - 2019), Boston Business Journal’s 2019 Power 50, and the 2016 CPhl Pharma CEO of the Year.

Currently, Udit is a board member of Boston Children’s Hospital’s Trust Board and the Analytical, Life Science & Diagnostics Association (ALDA). He also serves on the Advisory Councils of the Chemical Engineering Departments of Princeton University where he earned his Ph.D. in Chemical Engineering and the University of Delaware where he earned a B.S. in Chemical Engineering.

Keeley Aleman was appointed Senior Vice President, General Counsel and Secretary for Waters Corporation in 2019. She is responsible for all legal matters globally and for Waters’ environmental, social, and governance program.

Keeley joined Waters Corporation in 2006 as the Assistant General Counsel. In her time at Waters, she has served in various roles of increasing responsibility, including as Vice President, Deputy General Counsel and Assistant Secretary, Associate General Counsel and Assistant General Counsel for Waters. She advises on business transactions, commercial strategies, mergers and acquisitions, intellectual property, compliance, corporate governance, and organizational matters.

Prior to joining Waters, Keeley was an attorney with Goodwin Procter LLP and Testa, Hurwitz & Thibeault, LLP.

Massachusetts’s Lawyer Weekly recognized Keeley in 2017’s Top Women of the Law.

She earned her B.A., with honors, from University of California at Davis and received her J.D., magna cum laude, from Boston University School of Law.

Jianqing Bennett was appointed Senior Vice President of the TA Instruments Division of Waters Corporation in 2021 and assumed leadership of the Clinical Business Unit in 2022. She is responsible for leading the TA Instruments Division into high-growth markets with analytical solutions for materials and life sciences customers, as well as establishing the Waters Clinical Business as an industry leader in mass spectrometry diagnostics.

Prior to joining Waters, Jianqing was Senior Vice President, High Growth Markets at Beckman Coulter Diagnostics (a Danaher operating company), where she was responsible for the P&L of High Growth Markets and managed the full portfolio of in vitro clinical core laboratory solutions, helping to accelerate revenue growth and market share gain. Prior to Beckman Coulter Diagnostics, she served in roles of increasing responsibility over 14 years at Carestream Health, including President of the Medical Digital Business from 2015 to 2017.

Prior to Carestream Health, Jianqing served in multiple roles at GE Healthcare Inc. in the U.S. from 2001 to 2003 and China from 1995 to 1999.

She holds a B.S. in biomedical engineering from Fudan University in Shanghai, China and an MBA in management information systems from The University of Iowa.

Rob Carpio was appointed Senior Vice President of the Waters Division in 2024. He is responsible for liquid chromatography (LC) and mass spectrometry (MS) instruments, consumables, informatics, sales, marketing, and service. He oversees cross-functional collaboration of the product development and commercial teams as well as overall global strategic planning for the Waters Division.

Prior to joining Waters, Rob served as Group President of Life Sciences at Madison Industries’ Filtration Group. While at Madison, Rob led a number of decentralized business units (BU), culminating in his most recent role leading the eight life sciences focused BUs with 2,400 employees globally supplying specialty components & materials across the life sciences application landscape. Prior to Madison, Rob held positions of increasing global responsibility at Precision Castparts Corporation, Alcoa Corporation, and McKinsey & Company. Rob began his career in the United States Army, serving both on active duty and as a member of the Massachusetts National Guard. 

Rob earned a B.S. in systems engineering from the United States Military Academy at West Point, a master’s in human relations from the University of Oklahoma, and an MBA with Distinction from Harvard Business School.

Amol Chaubal was appointed Chief Financial Officer of Waters Corporation in 2021. He is responsible for all aspects of the Finance and Information Technology organizations and is focused on executing Waters’ transformation strategy and building long-term value creation.

Prior to joining Waters, Amol was Chief Financial Officer at Quanterix since 2019 where he helped oversee a period of strong shareholder value creation and returns. From 2017 to 2019, Amol was Chief Financial Officer of Global Operations at Smith & Nephew. Prior to Smith & Nephew, he served as Corporate Vice President and Head of Finance for PAREXEL’s Clinical Research Services and Access businesses from 2015 to 2017. Between 2013 and 2015, he was the North America Chief Financial Officer and later Regional Chief Operating Officer at Brookfield Renewable Energy Group, part of Brookfield Asset Management. Prior to Brookfield, Amol was Chief Financial Officer North America at Novartis Vaccines & Diagnostics and spent 11 years with Novartis in positions of increasing responsibility across Switzerland, Canada, and the United States. He began his career with Procter & Gamble.

He earned a master’s in chemical engineering from Indian Institute of Technology, Mumbai and an MBA from INSEAD, France.

Kristen Garvey was appointed Vice President of Corporate Communications of Waters Corporation in 2019 after joining the company in 2018. She is responsible for Waters’ communication strategy across multiple stakeholder groups and oversees public relations, corporate branding, community involvement, and executive and employee communications. Kristen leads the effort to drive affinity and awareness for the Waters brand globally.

Prior to joining Waters, Kristen led internal communications at EMC and Dell Technologies, playing a significant role in the communication strategy for the largest technology merger in IT history. A marketer at heart, Kristen has held a variety of marketing leadership positions at Chadwick Martin Bailey and DataViz.

Kristen serves on the Board of The New England Council and the Boston Chamber Women’s Network Advisory Board. She earned a B.A. in communications from the University of Massachusetts Amherst.

Cheryl Kennedy was appointed Senior Vice President, Human Resources of Waters Corporation in 2024. She is responsible for providing end-to-end leadership, learning and development, succession planning, talent acquisition, Total Rewards, HR operations and technology, employee engagement, and diversity and inclusion.

Prior to joining Waters, Cheryl was Chief Human Resources Officer at Ascend Learning, a Blackstone portfolio company, where she was instrumental in accelerating the Company's enterprise strategy by enhancing organizational effectiveness and building leadership capabilities to drive growth. Previously, Cheryl played a pivotal role as Chief Human Resources and Sustainability Officer for Welch's, where she led the alignment of culture, talent, and business strategies, helping triple the Company's profits in three years. Prior to Welch’s, she spent over a decade at Hasbro in roles of increasing responsibility, ultimately becoming their Senior Vice President of Human Resources. Earlier in her career, Cheryl was a Human Capital and Rewards Consultant advising both management and board of directors across a variety of industries. 

She earned a B.A. in General Studies and her MBA in Finance from the University of Rhode Island.

Chris Ross was appointed Senior Vice President, Global Operations of Waters Corporation in 2022. He is responsible for Waters worldwide Manufacturing, Supply Chain & Distribution, Facilities, Health & Safety, Procurement and Quality.

Prior to joining Waters, Chris spent the last 14 years at MilliporeSigma, the $9 billion Life Science business of Merck KGaA, Darmstadt, Germany, where he was most recently the Interim Sector Head of Life Science and Head of Integrated Supply Chain Operations. As Interim Sector Head of Life Science, he was responsible for leading the strategic direction of the business collaborating with the global scientific community to solve the industry's toughest problems, making research and biotech production simpler, faster, and safer. As Head of Integrated Supply Chain Operations, he was responsible for global manufacturing, supply chain, and global distribution driving improvements in cost, quality, and delivery of products. He was appointed US Country Speaker for Merck KGaA, Darmstadt, Germany in 2019, driving a one-company approach and representing the company across the United States.

Chris serves on the board of The New England Council and Boston Chamber of Commerce. He earned an MBA from the University of Washington in Seattle and a B.S. in electrical engineering from Worcester Polytechnic Institute.

Dr. Daniel Rush was appointed Senior Vice President, Strategy and Transformation of Waters Corporation in 2021. In this role, he collaborates with the Executive Committee to develop and operationalize worldwide enterprise strategy, shares responsibility for M&A, and leads the Global Research function.

Prior to joining Waters, Dan served as Vice President, Worldwide Commercialization Strategy & Innovation at Bristol Myers Squibb (BMS), where he led its digital customer model transformation and was responsible for implementing a novel innovation system across Commercial, Medical and Market Access. Prior to BMS, he spent eight years at Novartis in a variety of sales, marketing, and strategy leadership roles, including Head of Global Pharma Strategy, U.S. Launch Lead for Afinitor® and U.S. Marketing Director for Zometa®.

Dan began his career as a chemist in Pharmaceutical R&D at Merck, following a post-doc in materials science at the University of California, Irvine and Sandia National Laboratories.

He earned a B.A. in chemistry and history from Bowdoin College and a Ph.D. in physical organic chemistry from Yale University.

Board of Directors

Chair of the Board, Chief Executive Officer, Galderma

Dr. Flemming Ornskov is currently CEO of Galderma (since 2019), a healthcare company focused on dermatology. 

He brings operational and medical knowledge along with extensive international, strategic planning and operational experience in the healthcare sector having an extensive career serving in senior leadership roles and on boards at a number of global pharmaceutical, biotechnology and healthcare companies. 

Dr. Ornskov qualified as a Doctor of Medicine at the University of Copenhagen Medical School and earned a Master of Public Health (MPH) from Harvard University School of Public Health and an MBA from INSEAD.

President and Chief Executive Officer, Waters

Dr. Batra is currently President and Chief Executive Officer of Waters, a position he has held since 2020.

He brings more than two decades of leadership and operational expertise in the healthcare and life sciences industries, including leadership of multi-billion-dollar global organizations.

Dr. Batra received a B.S. from the University of Delaware and a PhD in Chemical Engineering from Princeton University.

Former EVP and Chief Financial Officer, PRA Health Sciences

Ms. Baddour is the former Executive Vice President and CFO of PRA Health Sciences (2007 – 2018).

She provides the Waters Board with significant accounting, finance and health care industry expertise, gained through her extensive experience as a senior financial executive across healthcare, life sciences, and pharmaceutical services and banking companies.

Ms. Baddour is also a certified public accountant and received a B.A. and MBA from the University of North Carolina at Wilmington.

Executive Vice President and Chief Financial Officer, Boston Scientific Corporation

Mr. Brennan is currently an independent director.

He brings more than two decades of finance leadership in the medical device industry, including at a multi-billion-dollar global organization where he is responsible for all financial operations, business development and strategic development. During his time at Boston Scientific, he helped oversee successful margin and revenue growth initiatives. He also possesses public company Board experience.

Mr. Brennan is a certified public accountant and earned a B.S. and an MBA from Babson College.

Former Vice Chairman and Chief Financial and Planning Officer, Eaton Corporation

Mr. Fearon is currently an independent director.

He brings international business experience with expertise in accounting, corporate development (M&A), information systems, internal audit, investor relations, and strategic planning to the Waters Board. He also possesses significant public company Board experience.

Mr. Fearon received an A.B. from Stanford University and a J.D. and an MBA from Harvard University.

President and Chief Executive Officer, Dunad Therapeutics

Dr. Huang is currently President and Chief Executive of Dunad Therapeutics, a Novartis-backed biopharmaceutical startup (since May 2022).

She brings deep scientific knowledge along with extensive international and operational experience in the pharmaceutical sector both in senior leadership and operational roles.

Dr. Huang earned a B.S. in biology from MIT and a Ph.D. in molecular biology from Princeton University.

Former EVP, President of Pharmaceuticals Region China & Asia Pacific, and President, Bayer Group Greater China Region, Bayer AG

Mr. Jiang is currently an independent director.

His more than 25 years' experience in the pharmaceutical and medical device industries, with particular focus in China and the Asia/Pacific region at large allows him to bring experienced international perspective to the Waters Board.

Mr. Jiang received a MA in economics and finance from Indiana State University and a BBA from Campbell University.

Executive Vice President and Group President, Medical Products & Therapies, Baxter International

Ms. Knight is currently Executive Vice President and Group President, Medical Products and Therapies of Baxter International (since 2023).

She brings nearly three decades of global business and commercial leadership experience in the pharmaceutical and medical device industries, and a proven track record of driving strong execution, business transformation, and portfolio innovation.

Ms. Knight received a B.S. from the University of Buffalo.

Former Chairman and Chief Executive Officer, Covance

Mr. Kuebler is currently an independent director and investor.

His 30 years of experience in the pharmaceutical and pharmaceutical service industries, including 10 years as Chairman and Chief Executive Officer of Covance allows him to bring an experienced management perspective to the Waters Board, as well as expertise in the oversight of financial accounting and business strategy.

Mr. Kuebler earned a B.S. in biology from Florida State University.

Former Chairman, President and Chief Executive Officer, The Chemours Company

Mr. Vergnano is currently an independent director.

He provides the Waters Board with significant senior executive leadership at global sciences companies. Mr. Vergnano brings deep operational experience and a proven track record of business transformation and consistent growth at The Chemours Company and DuPont. He also possesses public company Board experience.

Mr. Vergnano received a B.S. from the University of Connecticut and an MBA from Virginia Commonwealth University.

Learn more about our Committee Composition.

Back To Top Back To Top